Targeted Therapy, Immunotherapy, and Molecular Testing in Advanced Solid Tumors: A Medicare Analysis

Onur Baser, Yijia Sun · 2026

Read Targeted Therapy, Immunotherapy, and Molecular Testing in Advanced Solid Tumors: A Medicare Analysis by Onur Baser, Yijia Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601854.txt.

Description

Onur Baser and Yijia Sun analyzed Medicare records on gene testing and matched therapy in advanced cancers, in this 2026 study. Precision drugs hinge on finding the right mutation first. Older patients' real-world uptake was little known.

Nearly 40,000 patients with four cancer types were covered. Only about a fifth got biomarker testing, and under a tenth had an actionable change. Of those, 62 percent got matched first-line therapy. Testing slightly lengthened the wait for treatment but caused no survival penalty. Testing linked to longer survival, and matched therapy to better daily function at six months. The authors see wide room to widen testing.

Catalog record

CREATOROnur Baser, Yijia Sun
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13601854

Browse the full library · About the Tower of Babel